NZ334613A
(en)
*
|
1996-08-12 |
2002-02-01 |
Welfide Corp |
Pharmaceutical agents comprising Rho kinase inhibitor
|
WO1999054306A1
(fr)
*
|
1997-03-10 |
1999-10-28 |
Hiroyoshi Hidaka |
Derives isoquinolinesulfonamide et medicaments integrant ces derives comme principe actif
|
US20080233098A1
(en)
*
|
1997-10-31 |
2008-09-25 |
Mckerracher Lisa |
RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth
|
ES2372572T3
(es)
*
|
1998-08-17 |
2012-01-23 |
Senju Pharmaceutical Co., Ltd. |
Agente para profilaxis y tratamiento de glaucoma.
|
US7169783B2
(en)
*
|
1998-11-02 |
2007-01-30 |
Universite De Montreal |
(+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
|
AU3328600A
(en)
*
|
1999-03-25 |
2000-10-16 |
Santen Pharmaceutical Co. Ltd. |
Ocular tension-lowering agents
|
ATE374026T1
(de)
*
|
1999-03-25 |
2007-10-15 |
Mitsubishi Pharma Corp |
Rho-kinase-inhibitoren für die vorbeugung oder behandlung von interstitieller pneumonie und pulmonaler fibrose
|
CA2369552A1
(en)
*
|
1999-04-22 |
2000-11-02 |
Hisashi Kai |
Agent for prophylaxis and treatment of angiostenosis
|
DE60045890D1
(de)
*
|
1999-04-27 |
2011-06-09 |
Mitsubishi Tanabe Pharma Corp |
Arzneimittel zur präventiven oder therapeutische Behandlung von Lebererkrankungen
|
WO2000078351A1
(fr)
*
|
1999-06-18 |
2000-12-28 |
Mitsubishi Pharma Corporation |
Promoteurs de l'osteogenese
|
JP2001081031A
(ja)
*
|
1999-08-30 |
2001-03-27 |
Schering Ag |
溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
|
AU6865100A
(en)
*
|
1999-09-02 |
2001-04-10 |
Mitsubishi Pharma Corporation |
Osteogenesis promoting agents
|
AU7451200A
(en)
*
|
1999-09-29 |
2001-04-30 |
Mitsubishi Pharma Corporation |
Analgesics
|
US7217722B2
(en)
|
2000-02-01 |
2007-05-15 |
Kirin Beer Kabushiki Kaisha |
Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
|
ATE327993T1
(de)
*
|
2000-03-16 |
2006-06-15 |
Mitsubishi Pharma Corp |
Amid-verbindung und deren verwendung
|
CA2404594C
(en)
|
2000-03-31 |
2010-12-21 |
Mitsubishi Pharma Corporation |
Agent for prophylaxis and treatment of renal disease
|
ATE465756T1
(de)
|
2000-06-23 |
2010-05-15 |
Mitsubishi Tanabe Pharma Corp |
Antitumoreffekt-verstärker
|
BR0114021A
(pt)
*
|
2000-09-20 |
2003-08-19 |
Merck Patent Gmbh |
4-amino-quinazolinas
|
US7547702B2
(en)
*
|
2000-09-20 |
2009-06-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
4-amino-quinazolines
|
JP4582561B2
(ja)
*
|
2000-10-23 |
2010-11-17 |
旭化成ファーマ株式会社 |
移植による血管病変の発生抑制剤
|
JP2002139493A
(ja)
*
|
2000-11-01 |
2002-05-17 |
Sumitomo Pharmaceut Co Ltd |
新規なハイスループット・スクリーニング方法
|
CA2325842C
(en)
*
|
2000-11-02 |
2007-08-07 |
Lisa Mckerracher |
Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
|
US20020177207A1
(en)
*
|
2001-03-14 |
2002-11-28 |
Myriad Genetics, Incorporated |
Tsg101-interacting proteins and use thereof
|
WO2002053143A2
(en)
*
|
2001-01-05 |
2002-07-11 |
The Medical College Of Georgia Research Institute, Inc. |
Treatment of erectile dysfunction with rho-kinase inhibitors
|
JP2002226375A
(ja)
*
|
2001-01-31 |
2002-08-14 |
Asahi Kasei Corp |
線維化予防、治療剤
|
WO2002098370A2
(en)
*
|
2001-03-02 |
2002-12-12 |
Medimmune, Inc. |
Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
|
DE60211317T2
(de)
*
|
2001-03-23 |
2007-04-12 |
Bayer Corp. |
Rho-kinase inhibitoren
|
PT1370552E
(pt)
*
|
2001-03-23 |
2007-04-30 |
Bayer Pharmaceuticals Corp |
Inibidores de rho-quinase
|
CA2707827A1
(en)
*
|
2001-04-11 |
2002-10-24 |
Senju Pharmaceutical Co., Ltd. |
Visual function disorder improving agents containing rho kinase inhibitors
|
US7442686B2
(en)
|
2001-04-12 |
2008-10-28 |
Bioaxone Therapeutique Inc. |
Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
|
EP1403255A4
(en)
*
|
2001-06-12 |
2005-04-06 |
Sumitomo Pharma |
INHIBITORS OF RHO KINASE
|
JP5042419B2
(ja)
*
|
2001-08-15 |
2012-10-03 |
旭化成ファーマ株式会社 |
骨形成促進剤および骨形成促進組成物
|
US7829566B2
(en)
*
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
DE10153605A1
(de)
*
|
2001-11-02 |
2003-05-28 |
Morphochem Ag Komb Chemie |
Verwendung von Inhibitoren der Rho-Kinasen zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens
|
WO2003047591A1
(en)
*
|
2001-11-30 |
2003-06-12 |
Asahi Kasei Pharma Corporation |
Remedies for primary pulmonary hypertension
|
FR2833840B1
(fr)
*
|
2001-12-21 |
2010-06-18 |
Rytek |
Methodes et compositions pour le traitement de pathologies respiratoires
|
US20040014755A1
(en)
*
|
2002-01-10 |
2004-01-22 |
Dhanapalan Nagarathnam |
Rho-kinase inhibitors
|
WO2003062227A1
(en)
*
|
2002-01-23 |
2003-07-31 |
Bayer Pharmaceuticals Corporation |
Rho-kinase inhibitors
|
CA2473510A1
(en)
*
|
2002-01-23 |
2003-07-31 |
Bayer Pharmaceuticals Corporation |
Pyrimidine derivatives as rho-kinase inhibitors
|
GB0206860D0
(en)
*
|
2002-03-22 |
2002-05-01 |
Glaxo Group Ltd |
Compounds
|
US7645878B2
(en)
*
|
2002-03-22 |
2010-01-12 |
Bayer Healthcare Llc |
Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
|
AU2003220935A1
(en)
*
|
2002-04-03 |
2003-10-13 |
Sumitomo Pharmaceuticals Company, Limited. |
Benzamide derivatives
|
US20040028716A1
(en)
*
|
2002-06-14 |
2004-02-12 |
Marks Andrew R. |
Use of Y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
WO2004006947A1
(en)
*
|
2002-07-12 |
2004-01-22 |
Yihai Cao |
A method for inhibiting vascular permeability and tissue edema
|
US7094789B2
(en)
|
2002-07-22 |
2006-08-22 |
Asahi Kasei Pharma Corporation |
5-substituted isoquinoline derivatives
|
WO2004009555A1
(ja)
*
|
2002-07-22 |
2004-01-29 |
Asahi Kasei Pharma Corporation |
5−置換イソキノリン誘導体
|
DE10233737A1
(de)
*
|
2002-07-24 |
2004-02-05 |
Morphochem Aktiengesellschaft für kombinatorische Chemie |
Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen
|
WO2004016739A2
(en)
*
|
2002-08-01 |
2004-02-26 |
Caritas St. Elizabeth's Medical Center Of Boston, Inc. |
Cell modulation using a cytoskeletal protein
|
TWI350170B
(en)
*
|
2002-08-29 |
2011-10-11 |
Santen Pharmaceutical Co Ltd |
Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin
|
CA2400996A1
(en)
*
|
2002-09-03 |
2004-03-03 |
Lisa Mckerracher |
1,4-substituted cyclohexane derivatives
|
CN100383140C
(zh)
*
|
2002-09-12 |
2008-04-23 |
麒麟麦酒株式会社 |
具有激酶抑制活性的异喹啉衍生物和包含异喹啉衍生物的药剂
|
US20050215601A1
(en)
*
|
2002-09-25 |
2005-09-29 |
Santen Pharmaceutical Co., Ltd. |
Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient
|
US8034831B2
(en)
*
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
WO2004045644A1
(ja)
*
|
2002-11-18 |
2004-06-03 |
Santen Pharmaceutical Co., Ltd. |
Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
|
AU2004221792C1
(en)
*
|
2003-03-18 |
2009-09-24 |
Medvet Science Pty. Ltd. |
A method of modulating smooth muscle cell functioning by modulating sphingosine kinase mediated signalling
|
AU2003901270A0
(en)
*
|
2003-03-18 |
2003-04-03 |
Medvet Science Pty. Ltd. |
A method of modulating muscle cell functioning
|
GB2400316A
(en)
*
|
2003-04-10 |
2004-10-13 |
Richard Markoll |
Electromagnetic stimulation in patients with osteoporosis
|
KR20120035234A
(ko)
|
2003-04-11 |
2012-04-13 |
메디뮨 엘엘씨 |
재조합 il?9 항체 및 그의 용도
|
ATE525111T1
(de)
*
|
2003-04-18 |
2011-10-15 |
Senju Pharma Co |
2-chloro-6,7-dimethoxy-n-5 ä5-(1)h- indazolylüquinazolin-4-amin, n-(1-benzyl-4- piperidinyl)-1h-indazol-5-amin dihydrochlorid, 4- ä2-(2,3,4,5,6-
|
WO2004105757A2
(en)
*
|
2003-05-29 |
2004-12-09 |
Schering Aktiengesellschaft |
Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
|
US20110098232A1
(en)
*
|
2003-05-30 |
2011-04-28 |
Zeilig Charles E |
Methods For The Selective Treatment Of Tumors By Calcium-Mediated Induction Of Apoptosis
|
WO2004108142A2
(en)
*
|
2003-06-06 |
2004-12-16 |
The University Of Manchester |
Inhibitors of tip-1 for treatment tissue damage
|
US7160894B2
(en)
|
2003-06-06 |
2007-01-09 |
Asahi Kasei Pharma Corporation |
Tricyclic compound
|
US7417026B2
(en)
*
|
2003-08-13 |
2008-08-26 |
Children's Hospital Medical Center |
Mobilization of hematopoietic cells
|
JP2007535479A
(ja)
|
2003-08-13 |
2007-12-06 |
チルドレンズ ホスピタル メディカル センター |
GTPaseを調節するためのキメラペプチド
|
WO2005042743A2
(en)
|
2003-08-18 |
2005-05-12 |
Medimmune, Inc. |
Humanization of antibodies
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
US7371850B1
(en)
*
|
2003-08-20 |
2008-05-13 |
Myriad Genetics, Inc. |
Method and composition for reducing expression of ROCK-II
|
CN1863779B
(zh)
|
2003-10-15 |
2010-05-05 |
宇部兴产株式会社 |
吲唑衍生物
|
WO2005056024A1
(en)
*
|
2003-12-05 |
2005-06-23 |
Children's Hospital Medical Center |
Methods of enhancing stem cell engraftment
|
CA2550361C
(en)
|
2003-12-19 |
2014-04-29 |
Prabha Ibrahim |
Compounds and methods for development of ret modulators
|
WO2005063249A1
(en)
*
|
2003-12-22 |
2005-07-14 |
Alcon, Inc. |
Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
|
ZA200604862B
(en)
*
|
2003-12-22 |
2007-10-31 |
Alcon Inc |
Agents for treatment of glaucomatous retinopathy and optic neuropathy
|
TW200526224A
(en)
*
|
2003-12-22 |
2005-08-16 |
Alcon Inc |
Short form c-Maf transcription factor antagonists for treatment of glaucoma
|
JP2007523202A
(ja)
*
|
2004-02-24 |
2007-08-16 |
ビオアクソン・テラプティーク・インコーポレーテッド |
4置換ピペリジン誘導体
|
WO2005094824A1
(en)
*
|
2004-03-25 |
2005-10-13 |
East Carolina University |
Methods of enhancing cancer therapy by protecting nerve cells
|
US20050222127A1
(en)
*
|
2004-03-30 |
2005-10-06 |
Alcon, Inc. |
Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
|
US20060115870A1
(en)
*
|
2004-03-30 |
2006-06-01 |
Alcon, Inc. |
High throughput assay for human Rho kinase activity
|
US20080096238A1
(en)
*
|
2004-03-30 |
2008-04-24 |
Alcon, Inc. |
High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
|
DK1734996T3
(da)
|
2004-04-02 |
2013-06-10 |
Univ California |
Fremgangsmåder og sammensætninger til behandling og forebyggelse af sygdom, der er associeret med alfa v beta 5-integrin
|
CN1795196B
(zh)
*
|
2004-06-03 |
2013-07-24 |
千寿制药株式会社 |
酰胺化合物在制备用于修复角膜敏感性的药剂中的应用
|
AU2005299355A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Llc |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
FR2879100B1
(fr)
|
2004-12-09 |
2007-07-06 |
Lionel Bueno |
Compositions pour le traitement des pathologies oculaires de surface et de la retine
|
AR054416A1
(es)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
ES2368338T3
(es)
*
|
2004-12-27 |
2011-11-16 |
Novartis Ag |
Análogos de aminopirazina para el tratamiento del glaucoma y otras enfermedades mediadas por la rho cinasa.
|
WO2007076360A1
(en)
*
|
2005-12-22 |
2007-07-05 |
Alcon Research, Ltd. |
(indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
|
EP1854484A4
(en)
*
|
2005-02-16 |
2010-02-10 |
Astellas Pharma Inc |
REMEDY FOR PAIN CONTAINING INHIBITOR OF RHO-KINASE PROTEIN
|
JP5153613B2
(ja)
|
2005-03-18 |
2013-02-27 |
メディミューン,エルエルシー |
抗体のフレームワーク・シャッフル
|
CR9465A
(es)
|
2005-03-25 |
2008-06-19 |
Surface Logix Inc |
Compuestos mejorados farmacocineticamente
|
CA2613512A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
MX2008000017A
(es)
*
|
2005-06-28 |
2008-03-26 |
Sanofi Aventis |
Derivados de isoquinolina como inhibidores de rho-cinasa.
|
PT1910333E
(pt)
|
2005-07-26 |
2013-08-01 |
Sanofi Sa |
Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase
|
MX2008000956A
(es)
|
2005-07-26 |
2008-03-27 |
Sanofi Aventis |
Derivados de ciclohexilaminisoquinolona en calidad de inhibidores de rho-quinasa.
|
EP2258359A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation with sabcomelin
|
JP2009506069A
(ja)
|
2005-08-26 |
2009-02-12 |
ブレインセルス,インコーポレイティド |
ムスカリン性受容体調節による神経発生
|
KR101149954B1
(ko)
|
2005-08-30 |
2012-06-01 |
아사히 가세이 파마 가부시키가이샤 |
술폰아미드 화합물
|
KR20080040027A
(ko)
|
2005-09-02 |
2008-05-07 |
아스테라스 세이야쿠 가부시키가이샤 |
Rock 억제제로서 아미드 유도체
|
JP4832051B2
(ja)
*
|
2005-10-21 |
2011-12-07 |
学校法人順天堂 |
半月体形成性腎病変治療剤
|
AU2006304787A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
US7893050B2
(en)
|
2005-10-26 |
2011-02-22 |
Asahi Kasei Pharma Corporation |
Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
|
CA2625210A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
US7867999B1
(en)
|
2005-12-22 |
2011-01-11 |
Alcon Research, Ltd. |
Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
EP2377531A2
(en)
|
2006-05-09 |
2011-10-19 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
EP2026813A2
(en)
|
2006-05-09 |
2009-02-25 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
CA2653424A1
(en)
|
2006-06-08 |
2007-12-13 |
Ube Industries, Ltd. |
Novel indazole derivative having spiro ring structure in side chain
|
MX2009001037A
(es)
|
2006-07-31 |
2009-05-15 |
Senju Pharma Co |
Preparacion liquida acuosa que contiene compuesto de amida.
|
WO2008022182A1
(en)
*
|
2006-08-16 |
2008-02-21 |
The Uab Research Foundation |
Methods for promoting coupling between bone formation and resorption
|
MY162024A
(en)
|
2006-08-28 |
2017-05-31 |
La Jolla Inst Allergy & Immunology |
Antagonistic human light-specific human monoclonal antibodies
|
GB0617222D0
(en)
*
|
2006-08-31 |
2006-10-11 |
Vereniging Het Nl Kanker I |
Antibiotics
|
US7998971B2
(en)
|
2006-09-08 |
2011-08-16 |
Braincells Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
US20090036465A1
(en)
*
|
2006-10-18 |
2009-02-05 |
United Therapeutics Corporation |
Combination therapy for pulmonary arterial hypertension
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
WO2008079945A2
(en)
*
|
2006-12-20 |
2008-07-03 |
University Of South Florida |
Rock inhibitors and uses thereof
|
AR064420A1
(es)
*
|
2006-12-21 |
2009-04-01 |
Alcon Mfg Ltd |
Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
|
BRPI0720862A2
(pt)
|
2006-12-27 |
2014-02-25 |
Sanofi Aventis |
Derivados de isoquinolina e isoquinolinona substituídos como inibidores de rho-cinase
|
BRPI0720909A2
(pt)
|
2006-12-27 |
2016-11-01 |
Sanofi Aventis |
derivados de isoquinolina e isoquinolinona substituídos
|
JP5405316B2
(ja)
|
2006-12-27 |
2014-02-05 |
サノフイ |
シクロアルキルアミン置換イソキノリン誘導体
|
PT2102164E
(pt)
|
2006-12-27 |
2011-01-21 |
Sanofi Aventis |
Derivados de isoquinolina e de isoquinolinona substituída com cicloalquilamina
|
MY155009A
(en)
|
2006-12-27 |
2015-08-28 |
Sanofi Aventis |
Cycloalkylamine substituted isoquinolone derivatives
|
AU2007338408B2
(en)
|
2006-12-27 |
2012-07-26 |
Sanofi-Aventis |
Substituted isoquinoline and isoquinolinone derivatives
|
JP5419279B2
(ja)
*
|
2007-01-17 |
2014-02-19 |
ウィスコンシン アラムニ リサーチ ファンデーション |
改良された幹細胞の培養
|
US8415372B2
(en)
|
2007-02-27 |
2013-04-09 |
Asahi Kasei Pharma Corporation |
Sulfonamide compound
|
EP2130828A4
(en)
|
2007-02-28 |
2010-12-29 |
Asahi Kasei Pharma Corp |
sulfonamide
|
KR101566171B1
(ko)
|
2007-03-09 |
2015-11-06 |
삼성전자 주식회사 |
디지털 저작권 관리 방법 및 장치
|
EP2068923A4
(en)
|
2007-03-30 |
2010-11-24 |
Medimmune Llc |
ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES
|
US20100099640A1
(en)
*
|
2007-05-04 |
2010-04-22 |
Joannes Geuns |
Tissue degeneration protection
|
ES2396795T3
(es)
|
2007-07-02 |
2013-02-27 |
Asahi Kasei Pharma Corporation |
Compuesto de sulfonamida y cirstal del mismo
|
EP2170830B1
(en)
|
2007-07-17 |
2014-10-15 |
Plexxikon, Inc. |
2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS
|
WO2009028631A1
(ja)
*
|
2007-08-29 |
2009-03-05 |
Senju Pharmaceutical Co., Ltd. |
角膜内皮細胞接着促進剤
|
JP2011519973A
(ja)
*
|
2008-05-12 |
2011-07-14 |
アムネスティックス・インコーポレーテッド |
学習及び記憶を改善するための化合物関連出願に関する情報
|
EP2303845B1
(en)
|
2008-06-24 |
2013-09-18 |
Sanofi |
Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors
|
JP5713893B2
(ja)
|
2008-06-24 |
2015-05-07 |
サノフイ |
Rho−キナーゼ阻害剤としての置換イソキノリン類及びイソキノリノン類
|
CN102131785B
(zh)
|
2008-06-24 |
2014-10-29 |
赛诺菲-安万特 |
6-取代的异喹啉和异喹啉酮
|
EP2319539A4
(en)
|
2008-07-24 |
2012-03-28 |
Univ Osaka |
PROPHYLACTIC OR THERAPEUTIC AGENT FOR AXIAL MYOPIA
|
EP2331507A2
(en)
*
|
2008-09-18 |
2011-06-15 |
Astellas Pharma Inc. |
Heterocyclic carboxamide compounds
|
EP2177218A1
(en)
|
2008-10-15 |
2010-04-21 |
Medizinische Universität Wien |
Regenerative therapy
|
EP2177510A1
(en)
|
2008-10-17 |
2010-04-21 |
Universität des Saarlandes |
Allosteric protein kinase modulators
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
MY172424A
(en)
|
2009-04-03 |
2019-11-25 |
Hoffmann La Roche |
Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
WO2011021221A2
(en)
|
2009-08-17 |
2011-02-24 |
Reliance Life Sciences Pvt. Ltd. |
Compositions for spinal cord injury
|
WO2011047300A1
(en)
|
2009-10-16 |
2011-04-21 |
The Scripps Research Institute |
Induction of pluripotent cells
|
BR112012012156A2
(pt)
|
2009-11-06 |
2015-09-08 |
Plexxikon Inc |
compostos e métodos para modulação de cinase, e indicações para esta
|
CN102188697B
(zh)
*
|
2010-03-03 |
2014-11-05 |
中国医学科学院药物研究所 |
重组人Rho激酶在制备药物中的应用
|
CA2797033C
(en)
|
2010-04-22 |
2021-10-19 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
KR20140063501A
(ko)
|
2010-12-22 |
2014-05-27 |
페이트 세러퓨틱스, 인코포레이티드 |
단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
|
EP2668210B1
(en)
|
2011-01-26 |
2020-06-17 |
Celldex Therapeutics, Inc. |
Anti-kit antibodies and uses thereof
|
TR201816421T4
(tr)
|
2011-02-07 |
2018-11-21 |
Plexxikon Inc |
Kinaz modülasyonu için bileşikler ve metotlar ve bunların endikasyonları.
|
AR085279A1
(es)
|
2011-02-21 |
2013-09-18 |
Plexxikon Inc |
Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
|
EP2628482A1
(en)
|
2012-02-17 |
2013-08-21 |
Academisch Medisch Centrum |
Rho kinase inhiitors for use in the treatment of neuroblastoma
|
WO2013167475A1
(en)
*
|
2012-05-08 |
2013-11-14 |
Syddansk Universitet |
Anabolic compounds for treating and preventing bone loss diseases
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
BR112015001459B1
(pt)
|
2012-07-25 |
2023-02-14 |
Celldex Therapeutics, Inc |
Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo
|
WO2014059028A1
(en)
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
EP2968469A4
(en)
|
2013-03-15 |
2016-08-31 |
Longevity Biotech Inc |
PEPTIDES COMPRISING NON-ENDOGENIC AMINO ACIDS AND METHODS OF MAKING AND USING SAME
|
EP2990040B1
(en)
|
2013-04-24 |
2019-12-04 |
Kyushu University, National University Corporation |
Therapeutic agent for eyeground disease
|
WO2014177699A1
(en)
*
|
2013-05-03 |
2014-11-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Rhoa (rock) inhibitors for the treatment of enflammatory bowel disease
|
EP3003390B1
(en)
|
2013-06-06 |
2021-07-07 |
Pierre Fabre Médicament |
Anti-c10orf54 antibodies and uses thereof
|
RU2699289C2
(ru)
|
2013-08-26 |
2019-09-04 |
Байонтек Рисерч Энд Дивелопмент, Инк. |
НУКЛЕИНОВЫЕ КИСЛОТЫ, КОДИРУЮЩИЕ АНТИТЕЛА ПРОТИВ СИАЛИРОВАННОГО АНТИГЕНА ЛЬЮИСАа ЧЕЛОВЕКА
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
EP3604499A1
(en)
|
2014-03-04 |
2020-02-05 |
Fate Therapeutics, Inc. |
Improved reprogramming methods and cell culture platforms
|
AU2015271685B2
(en)
|
2014-06-04 |
2021-02-18 |
Biontech Research And Development, Inc. |
Human monoclonal antibodies to ganglioside GD2
|
JP2017522016A
(ja)
|
2014-06-27 |
2017-08-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
培養哺乳動物輪部幹細胞、その産生方法及びその使用
|
US10766959B2
(en)
|
2014-12-11 |
2020-09-08 |
Pierre Fabre Medicament |
Anti-C10ORF54 antibodies and uses thereof
|
US10857157B2
(en)
|
2015-01-26 |
2020-12-08 |
BioAxone BioSciences, Inc. |
Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
|
US10149856B2
(en)
|
2015-01-26 |
2018-12-11 |
BioAxone BioSciences, Inc. |
Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
|
US10106525B2
(en)
|
2015-01-26 |
2018-10-23 |
BioAxone BioSciences, Inc. |
Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
|
US10988534B2
(en)
|
2015-02-09 |
2021-04-27 |
Memorial Sloan Kettering Cancer Center |
Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof
|
CN114504652A
(zh)
|
2015-03-03 |
2022-05-17 |
科马布有限公司 |
抗体、用途和方法
|
WO2016210190A1
(en)
|
2015-06-24 |
2016-12-29 |
Nitto Denko Corporation |
Ionizable compounds and compositions and uses thereof
|
US20180296474A1
(en)
|
2015-10-13 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
|
EP4088719A1
(en)
|
2015-10-13 |
2022-11-16 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
|
JP7263005B2
(ja)
|
2015-10-16 |
2023-04-24 |
フェイト セラピューティクス,インコーポレイテッド |
基底状態の多能性の誘導及び維持に関するプラットフォーム
|
EP3909983A1
(en)
|
2015-12-02 |
2021-11-17 |
STCube & Co. Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
EP3383908A1
(en)
|
2015-12-02 |
2018-10-10 |
Stsciences, Inc. |
Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
US11198680B2
(en)
|
2016-12-21 |
2021-12-14 |
BioAxone BioSciences, Inc. |
Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
|
JP7369038B2
(ja)
|
2017-05-31 |
2023-10-25 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1に免疫特異的に結合する抗体及び分子並びにその治療的使用
|
JP2020522512A
(ja)
|
2017-05-31 |
2020-07-30 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
|
JP2020522562A
(ja)
|
2017-06-06 |
2020-07-30 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法
|
WO2019014322A1
(en)
*
|
2017-07-11 |
2019-01-17 |
BioAxone BioSciences, Inc. |
KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
|
US11707522B2
(en)
|
2017-10-13 |
2023-07-25 |
Boehringer Ingelheim International Gmbh |
Human antibodies to Tn antigen
|
CN111479568A
(zh)
|
2017-12-21 |
2020-07-31 |
参天制药株式会社 |
司培前列素与Rho激酶抑制剂的组合药物
|
AU2019306165A1
(en)
|
2018-07-20 |
2021-02-25 |
Pierre Fabre Medicament |
Receptor for vista
|
US20210292766A1
(en)
|
2018-08-29 |
2021-09-23 |
University Of Massachusetts |
Inhibition of Protein Kinases to Treat Friedreich Ataxia
|
UY38427A
(es)
|
2018-10-26 |
2020-05-29 |
Novartis Ag |
Métodos y composiciones para terapia con células oculares
|
CN111116555B
(zh)
*
|
2018-10-30 |
2023-06-02 |
北京盈科瑞创新药物研究有限公司 |
一种Rho激酶抑制剂及其制备方法和应用
|
WO2020193802A1
(en)
|
2019-03-28 |
2020-10-01 |
Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe |
Polymeric conjugates and uses thereof
|
EP4142879A1
(en)
|
2020-04-27 |
2023-03-08 |
Novartis AG |
Methods and compositions for ocular cell therapy
|
CN111707831A
(zh)
*
|
2020-07-16 |
2020-09-25 |
首都医科大学附属北京朝阳医院 |
Rock激酶活性在辅助诊断sle以及评价sle病情中的应用
|
CA3207859A1
(en)
|
2021-01-11 |
2022-07-14 |
Incyte Corporation |
Combination therapy comprising jak pathway inhibitor and rock inhibitor
|
CN113262226B
(zh)
*
|
2021-04-19 |
2023-05-16 |
杭州市第一人民医院 |
利舒地尔在制备细菌感染治疗药物中的应用
|
CA3235384A1
(en)
|
2021-10-18 |
2023-04-27 |
Takahiro Ochiya |
Compositions and methods of use thereof for treating liver fibrosis
|
CA3235862A1
(en)
|
2021-10-22 |
2023-04-27 |
Takahiro Ochiya |
Methods for making extracellular vesicles, and compositions and methods of use thereof
|
WO2023122213A1
(en)
|
2021-12-22 |
2023-06-29 |
Byomass Inc. |
Targeting gdf15-gfral pathway cross-reference to related applications
|
WO2023147107A1
(en)
|
2022-01-31 |
2023-08-03 |
Byomass Inc. |
Myeloproliferative conditions
|